Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials
FGFRi are effective treatment strategies for patients with advanced solid tumors harboring <i>FGFR</i> alterations, with manageable toxicities in most patients.
Authors
- Elisa Fontana (ORCID: https://orcid.org/0000-0002-4991-9355)
- Rafael Grochot (ORCID: https://orcid.org/0000-0002-2156-9197)
- Hendrik‐Tobias Arkenau (ORCID: https://orcid.org/0000-0002-2015-1549)
- Charles Swanton (ORCID: https://orcid.org/0000-0002-4299-3018)
- Antonella Cammarota (ORCID: https://orcid.org/0000-0001-9967-4694)
- Vivek Subbiah (ORCID: https://orcid.org/0000-0002-6064-6837)
- Rachel Woodford (ORCID: https://orcid.org/0000-0002-9470-314X)
- Anja Williams (ORCID: https://orcid.org/0000-0002-4944-1558)
- Kroopa Joshi
- Gethini Sathanantham
Institutions
- Humanitas University (IT)
- Sarah Cannon Research Institute (GB)
- The Francis Crick Institute (GB)
- Sarah Cannon (US)
- University College London (GB)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1200/po-24-00896
- Citations
- 1
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.81